Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov 11;6(1):393.
doi: 10.1038/s41392-021-00812-z.

CAR-T: a potential gene carrier targeting solid tumor immune microenvironment

Minjie Wang  1 , Chaocai Zhang  2 , Xiaobing Jiang  3
Affiliations
Comment

CAR-T: a potential gene carrier targeting solid tumor immune microenvironment

Minjie Wang et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Effects of CAR-T cells delivery system in cancer. a CAR-T cells enter in tumor area and cause the first killing: CAR-T cells recognize CAR antigens in a major histocompatibility complex (MHC)-independent manner and mediate secretory killing and non-secretory killing. b Reprogramming tumor immunosuppressive microenvironment and stimulating endogenous T cells: CAR-T cells deliver EV-based gene therapy to limit the accumulation of myeloid-derived suppressor cells (MDSCs) and inhibit TGF-β1 signaling pathway. Meanwhile, it also promotes the development of inflammatory dendritic cells (DCs) and an activation of endogenous T cells. c Turning “cold tumor” to “hot tumor” for glioblastoma: CAR-T cells deliver peptide antigen to cancer cells with CAR antigen loss and totally relieve the immune escape of tumor cells through endogenous immunity
See this image and copyright information in PMC

Comment on

References

    1. Johnson LR, et al. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell. 2021;184:4981–4995.e4914. doi: 10.1016/j.cell.2021.08.004. - DOI - PMC - PubMed
    1. Li L, et al. Chimeric antigen receptor T-cell therapy in glioblastoma: current and future. Front Immunol. 2020;11:594271. doi: 10.3389/fimmu.2020.594271. - DOI - PMC - PubMed
    1. Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38:473–488. doi: 10.1016/j.ccell.2020.07.005. - DOI - PubMed
    1. Wan PK, Ryan AJ, Seymour LW. Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Mol. Ther. 2021;29:1668–1682. doi: 10.1016/j.ymthe.2021.04.015. - DOI - PMC - PubMed
    1. Le Rhun E, et al. Molecular targeted therapy of glioblastoma. Cancer Treat. Rev. 2019;80:101896. doi: 10.1016/j.ctrv.2019.101896. - DOI - PubMed

Publication types

Substances